2 weeks Ago By Defense World Staff
LPL Financial LLC lessened its holdings in Intellia Therapeutics, Inc. ( NASDAQ:NTLA – Free Report ) by 4.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.
The fund owned 54,041 shares of the company’s stock after selling 2,554 shares during the period. LPL Financial LLC owned 0.05% of Intellia Therapeutics worth $630,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Whipplewood Advisors LLC bought a new position in Intellia Therapeutics during the fourth quarter valued at about $40,000. Jones Financial Companies Lllp increased its holdings in shares of Intellia Therapeutics by 140.
9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after acquiring an additional 2,280 shares during the last quarter. Daiwa Securities Group Inc.
raised its stake in shares of Intellia Therapeutics by 80.6% in the 4th quarter. Daiwa Securities Group Inc.
now owns 5,151 shares of the company’s stock valued at $60,000 after acquiring an additional 2,299 shares in the last quarter. KBC Group NV lifted its holdings in Intellia Therapeutics by 62.4% in the 4th quarter.
KBC Group NV now owns 6,093 shares of the company’s stock worth $71,000 after purchasing an additional 2,340 shares during the last quarter. Finally, AdvisorNet Financial Inc boosted its position in Intellia Therapeutics by 96.4% during the fourth quarter.
AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock worth $118,000 after purchasing an additional 4,950 shares during the period. 88.77% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets A number of equities analysts have recently commented on the stock. Barclays dropped their price target on shares of Intellia Therapeutics from $55.00 to $26.
00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Truist Financial cut their target price on shares of Intellia Therapeutics from $90.00 to $50.
00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Wedbush restated a “neutral” rating and set a $10.00 price target (down from $14.
00) on shares of Intellia Therapeutics in a report on Friday, January 10th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd.
Finally, Wells Fargo & Company decreased their target price on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, February 28th.
Two analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $36.
68. Intellia Therapeutics Stock Performance Shares of NTLA stock opened at $8.11 on Thursday.
The firm has a fifty day moving average of $8.78 and a 200-day moving average of $11.99.
Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $28.
18. The stock has a market cap of $839.01 million, a price-to-earnings ratio of -1.
49 and a beta of 2.23. About Intellia Therapeutics ( Free Report ) Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics.
The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. Recommended Stories Five stocks we like better than Intellia Therapeutics What is the Nasdaq? Complete Overview with History Can IBM’s Q1 Earnings Spark a Breakout for the Stock? Comparing and Trading High PE Ratio Stocks S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? How to Plot Fibonacci Price Inflection Levels Fundamentally Sound, These 5 Stocks Sold Off Anyway Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
